Macrophage-derived VEGF-C reduces cardiac inflammation and prevents heart dysfunction in CVB3-induced viral myocarditis via remodeling cardiac lymphatic vessels.

BACKGROUND: Cardiac lymphatic vessels are important channels for cardiac fluid circulation and immune regulation. In myocardial infarction and chronic heart failure, promoting cardiac lymphangiogenesis is beneficial in reducing cardiac edema and inflammation. However, the specific involvement of cardiac lymphangiogenesis in viral myocarditis (VMC) has not been studied. Despite the recognized participation of macrophages in lymphangiogenesis, the contribution of macrophages to cardiac lymphangiogenesis in VMC is still unclear. METHODS: The male Balb/c mice with VMC were grouped according to the time to explore changes in inflammation, cardiac function and lymphangiogenesis. Adeno-associated virus (AAV) was used to determine the effect of cardiac lymphangiogenesis in VMC. Macrophage depletion and VEGF-CC156S treatment were used to investigate the connection between macrophages and cardiac lymphangiogenesis. RESULTS: Cardiac inflammation and lymphatic vessel density were both upregulated, peaking on day 7 following CVB3 infection. After treatment with AAV-sVEGFR3, lymphangiogenesis was inhibited, leading to worsened cardiac dysfunction and aggravated inflammation. However, these effects were reversed by AAV-VEGF-C treatment. Furthermore, macrophages infiltrated the inflamed myocardium and secreted VEGF-C. In vitro, VEGF-C was upregulated when RAW264.7 cells were co-cultured with CVB3. Macrophage depletion in mice with VMC inhibited lymphangiogenesis, while supplementation with VEGF-CC156S depressed it. CONCLUSION: Collectively, these results indicate that activation of the VEGF-C/VEGFR3 axis exerts a protective effect in CVB3-induced VMC by resolving inflammation and alleviating cardiac dysfunction through increased lymphatic vasculature density, with macrophage-derived VEGF-C partially contributing to this effect.

COVID-19 vaccine uptake in a predominantly minoritized cohort hospitalized during the early pandemic in New York City.

BACKGROUND: Minoritized communities in the United States have had higher COVID-19 mortality and lower vaccine uptake. The influence of previous SARS-CoV-2 infection, initial disease severity, and persistent symptoms on COVID-19 vaccine uptake in Black and Latinx communities has not been examined. OBJECTIVE: To investigate whether initial COVID-19 severity, persistent symptoms, and other correlates affected vaccine uptake in a predominantly minoritized cohort hospitalized for COVID-19 during the early pandemic in New York City. DESIGN: In this historical cohort study, we abstracted electronic health record data on demographics, comorbidities, hospital oxygen requirements, symptoms at 3 and 6 months post-admission, COVID-19 vaccinations through November 2022, and influenza vaccinations during the 2018-2019 through 2021-2022 seasons. Unadjusted and adjusted odds ratios were estimated through logistic regression analyses of correlates of COVID-19 vaccination, on-time vaccination, and boosting. PARTICIPANTS: Survivors among the first 1186 adult patients hospitalized for COVID-19 between March 1 and April 8, 2020 at a large quaternary care medical center in Northern Manhattan. MAIN MEASURES: Uptake of at least one COVID-19 vaccine dose, uptake of at least one booster, and on-time vaccination. KEY RESULTS: The 890 surviving individuals were predominantly Latinx (54%) and Non-Hispanic Black (15%). Most had one or more comorbidities (67%), and received at least one COVID-19 vaccine dose (78%). Among those vaccinated, 57% received at least one booster, and 31% delayed vaccination. 67% experienced persistent symptoms. Multiple logistic regression showed no association between vaccine uptake and disease severity or symptom persistence. However, older age and influenza vaccination during the COVID-19 era were associated with increased vaccination, booster uptake, and on-time vaccination. CONCLUSIONS: Pinpointing drivers of vaccine uptake and hesitancy is critical to increasing and sustaining COVID-19 vaccination as the field transitions to annual boosters. The association between influenza vaccination and increased vaccine uptake suggests that bundling vaccines for adults may be an effective delivery strategy.

Twice-daily rivaroxaban after percutaneous left atrial appendage closure for atrial fibrillation.

Background and aim: Rivaroxaban is an emerging oral anticoagulant for postoperative anticoagulation after percutaneous left atrial appendage closure (LAAC). Because a once-daily dosing regimen of rivaroxaban causes fluctuations in the drug plasma concentration, we studied the feasibility and safety of twice-daily rivaroxaban as a postoperative anticoagulation regimen for patients with atrial fibrillation (AF) undergoing LAAC. Methods: This study involved patients with AF who underwent LAAC and took rivaroxaban postoperatively. A total of 326 patients who received a standard total dose (15 or 20 mg) of rivaroxaban based on their creatinine clearance rate were divided into the twice-daily (BID) rivaroxaban group (n = 208) and once-daily (QD) rivaroxaban group (n = 118) according to their anticoagulation strategy. Transesophageal echocardiography was recommended at 3-6 months postoperatively to check for device-related thrombosis (DRT). Clinical outcomes were evaluated during postoperative anticoagulation. Results: The median CHA2DS2-VASc score (4 [3, 5] vs. 4 [3, 5], p = 0.28) and HAS-BLED score (2 [2, 3] vs. 2 [2, 3], p = 0.48) were not significantly different between the groups. During the anticoagulation period (4.1 ± 0.7 vs. 4.1 ± 0.9 months, p = 0.58), 148 (71.2%) patients in the BID group and 75 (63.6%) in the QD group underwent follow-up transesophageal echocardiography. There were no statistically significant differences between the two groups in terms of DRT (1.4% vs. 2.7%, p = 0.60), minor bleeding (8.2% vs. 11.0%, p = 0.39), thromboembolic events (1.0% vs. 0.8%, p = 1.00), major bleeding (0.5% vs. 0.8%, p = 1.00), or death. Conclusion: A short course of twice-daily rivaroxaban following LAAC is a feasible alternative regimen with a low rate of major bleeding events, DRT, and thromboembolic events for patients with AF.

Plasmon-Activated Water can Prolong Existing Sea-Ice Habitats to Potentially Save Polar Bears.

Due to increasing global warming resulting from the greenhouse effect, subsequent environmental impacts and corresponding ecological influences are unavoidable. These problems are becoming more serious with time. Due to rising temperatures, the survival crisis of polar bears is a very often reported issue, because polar bears are encountering shortened seasons for catching prey on their sea-ice habitat. In this work, we report an innovative and facile strategy to save polar bears via prolonging the existence of ice layers based on plasmon-activated water (PAW). PAW with a reduced hydrogen-bonded network can be created by letting bulk deionized (DI) water flow through supported gold nanoparticles (AuNPs) under resonant illumination. Experimental results indicated that the freezing time of PAW was faster than that of DI water. In contrast, the melting time of frozen PAW was slower than that of the frozen DI water. Because the PAW with reduced hydrogen bonds (HBs) is in a high-energy state, it can more easily transform into a stronger HB structure in a low-energy state during cooling when freezing. This is accompanied by the release of more available energy, resulting in more-perfect tetrahedral symmetrical ice. Similar results were observed for solutions with 3 wt% NaCl, which is similar to the salinity of sea water. Moreover, the heat required to melt frozen PAW was ca. 7.6% higher than that of frozen DI water. These interesting phenomena suggest that prolonging the existence of solid ice can be achieved in a PAW-based system. Moreover, a system of AuNP-coated filter paper in DI water or in a DI water solution (3 wt% NaCl) under resonant illumination could work to prolong the presence of solid ice, compared to a system of AuNP-free filter paper. This innovative concept has emerged as a practical strategy to save polar bears and for other related applications.

Surface-enhanced Raman scattering-active gold nanoparticles modified with a monolayer of silver film.

As shown in the literature, electrochemical underpotential deposition (UPD) offers the ability to deposit up to a monolayer of one metal onto a more noble metal with a flat surface. In this work, we develop an electrochemical pathway to prepare more surface-enhanced Raman scattering (SERS)-active substrates with Ag UPD-modified Au nanoparticles (NPs) by using sonoelectrochemical deposition-dissolution cycles (SEDDCs). Encouragingly, the SERS of Rhodamine 6G (R6G) adsorbed on these Ag UPD-modified Au NPs exhibits a higher intensity by ca. 12-fold magnitude, as compared with that of R6G adsorbed on unmodified Au NPs. The prepared SERS-active substrate demonstrates a large Raman scattering enhancement for R6G with a detection limit of 2 × 10(-14) M and an enhancement factor of 5.0 × 10(8). Also, the strategy proposed in this work to improve the SERS effects by using UPD Ag based on SEDDCs has an effect on the smaller probe molecules of 2,2'-bipyridine (BPy).